Overview


According to FutureWise analysis the market for RNA Based Therapeutics and Vaccines in 2023 is US$ 8.19 billion, and is expected to reach US$ 32.53 billion by 2031 at a CAGR of 18.80%.

RNA therapeutics constitute an innovative category of medical interventions centered around ribonucleic acid (RNA). This domain encompasses diverse segments: messenger RNA (mRNA), antisense RNA (asRNA), RNA interference (RNAi), and RNA aptamers. Among these, mRNA-based therapy stands distinct due to its unique ability to spark protein synthesis within cells, which is particularly beneficial in vaccine development. Antisense RNA pairs with coding mRNA, instigating mRNA inactivation to halt its involvement in protein translation. RNA interference (RNAi) systems operate analogously, utilizing small interfering RNA (siRNA) and micro-RNA (miRNA) to obstruct mRNA translation and facilitate the disintegration of mRNA molecules.

In contrast, RNA aptamers, forged through directed evolution, consist of concise, single-stranded RNA molecules adept at binding firmly to diverse biomolecular targets, thereby shaping their inherent in vivo functions. RNA is transcribed from a template DNA through RNA polymerase, with messenger RNA (mRNA) acting as the intermediary molecule bridging DNA expression and protein translation. RNA's distinctive attributes, including its often single-stranded nature, the presence of a 2' OH group, and its capacity to adopt diverse secondary and tertiary structures, have ignited medical interest. Exploration into RNA's therapeutic potential has begun, introducing distinctive challenges during drug discovery and the execution of RNA-based therapeutics. Originating in the 1990s, this field has achieved remarkable milestones, particularly evident in cancer therapy during the early 2010s. 2020 and 2021 witnessed the global emergence of mRNA vaccines strategically designed to counter the COVID-19 pandemic. The Pfizer-BioNTech COVID-19 vaccine marked a momentous juncture as the pioneer mRNA vaccine sanctioned by regulatory entities, succeeded by the Moderna COVID-19 vaccine and subsequent candidates.

FutureWise Market Research has published a report that analyzes RNA-based Therapeutics and vaccine market trends affecting overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes the stature of key manufacturers operational in this industry. By the end of the forecast period, FutureWise research analysts project that the RNA-based therapeutics and Vaccines Market will experience significant growth.

According to the analysis, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help understand the growth opportunities held by various segments of this Market and further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corp.
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech AG
  • CureVac AG
  • Dicerna Pharmaceuticals, Inc.
  • Regulus Therapeutics, Inc.
  • Marina Biotech, Inc.
  • miRagen Therapeutics
  • Moderna Therapeutics, Inc.
  • Quark Pharmaceuticals, Inc.
  • Santaris Pharma A/S (A Roche Company)
  • Sylentis S.A.

Recent Development in RNA based Therapeutics and Vaccines Market

  • In November 2022, Health Canada approved using Moderna's Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine as a booster shot for individuals 18 and older. Previously, in September and October 2022, Health Canada had also given the go-ahead for similar bivalent booster doses containing the Omicron BA.1 or BA.4/5 variants. These boosters were developed by Moderna (50 mcg) and Pfizer-BioNTech (30 mcg), respectively.
  • In October 2022, Moderna Inc. announced the emergency use authorization (EUA) it had received from the United States Food and Drug Administration (FDA). Moderna's mRNA-1273.222 vaccine was approved as a bivalent COVID-19 booster, explicitly targeting the BA.4/BA.5 Omicron variants. This vaccine is now authorized for administration to Youngsters ranging from 6 to 17 years old, covering both children and adolescents.

By Product Type

  • RNA-based Therapeutics
    • sIRNA
    • miRNA
  • RNA-based Vaccines
    • mRNA

By Indication Type

  • Oncology
  • Immunology
  • Ophthalmology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Genetic Diseases
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. This can be attributed to its strong research and innovation hubs, substantial investment and funding, favorable regulatory environment, well-established biotech industry, successful response to the COVID-19 pandemic with RNA-based vaccines, advanced clinical trial infrastructure, collaborative partnerships, and a robust healthcare system. These factors have collectively propelled North America, particularly the United States, to a leading position in advancing and commercializing RNA-based medical technologies.

Drivers for RNA based Therapeutics and Vaccines Market

The development and adoption of RNA-based therapeutics and vaccines are propelled by various factors, with precision medicine as a significant driving force. RNA-based approaches empower personalized treatments, honing in on precise genetic mutations or molecular pathways. This precision allows for therapy to be intricately tailored to suit the unique requirements of individual patients, ushering in a new era of targeted and effective medical interventions. Additionally, RNA-based platforms facilitate the rapid development of vaccines and therapies, playing a pivotal role in combating emerging infectious diseases and their variants. The modular nature of RNA provides the flexibility to swiftly adapt and target new pathogens or mutations, bolstering our readiness to counter evolving health challenges. This technology also simplifies manufacturing processes by eliminating the need for live pathogens in RNA vaccines and therapies, reducing contamination risks. Furthermore, RNA vaccines possess high immunogenicity, triggering robust immune responses involving antibody production and T-cell activation. Notably, the low risk of genomic integration sets RNA-based treatments apart from gene therapies involving DNA, addressing long-term safety concerns. The versatility of RNA technologies spans a broad spectrum of diseases, encompassing infectious diseases, cancers, genetic disorders, and rare conditions. RNA's potential to target previously deemed "undruggable" proteins through RNA interference (RNAi) and antisense RNA (asRNA) opens new avenues for therapy. Moreover, the accelerated design and production of RNA vaccines significantly shorten the timeline from research to clinical application, a critical asset in managing pandemics and ensuring timely public health responses.

Restraints for RNA based Therapeutics and Vaccines Market

Expanding the RNA-based therapeutics and vaccines market encounters challenges and constraints that influence its progression. Overcoming delivery obstacles to ensure targeted and efficient delivery of RNA molecules and addressing concerns related to stability and degradation remain pivotal for optimizing treatment efficacy. Balancing the potent immunogenicity of RNA vaccines with careful management of potential adverse reactions is imperative. Striking a delicate equilibrium between on-target effects and off-target consequences is crucial for assuring the safety of RNA therapies. The market is further shaped by the ongoing need for comprehensive long-term clinical data to establish the durability of benefits. Navigating manufacturing intricacies, regulatory complexities, and cost considerations is pivotal to widespread accessibility and affordability. Public acceptance and understanding, competition from conventional therapies, and ethical considerations complete the challenges that must be navigated to unlock the full potential of RNA-based therapeutics and vaccines.

Opportunities for RNA based Therapeutics and Vaccines Market

The RNA-based therapeutics and vaccines market presents many opportunities driving growth and innovation. These include advancing personalized medicine, where RNA-based therapies precisely target genetic mutations for tailored treatments based on individual genetic profiles. The rapid development capabilities of RNA platforms position them as crucial assets for promptly addressing emerging infectious diseases. Furthermore, RNA therapies hold transformative potential in cancer treatment by honing in on specific genetic drivers of malignancies. Addressing rare diseases gains prominence with RNA-based approaches, drawing interest from pharmaceutical companies. The horizon broadens through RNA interference (RNAi) and antisense RNA (asRNA) technologies, enabling the targeting of previously challenging molecules. RNA vaccines contribute to global health preparedness by swiftly designing and manufacturing responses to pandemics and emerging health risks.

Trends for RNA based Therapeutics and Vaccines Market

The RNA-based therapeutics and vaccines market is witnessing dynamic trends reshaping the medical innovation landscape. Notably, advancements in delivery technologies are a focal point of ongoing research, as novel systems like lipid nanoparticles and viral vectors are being engineered to refine the precise and efficient delivery of RNA molecules to targeted cells or tissues. In a parallel trajectory, the utilization of artificial intelligence (AI) and computational approaches is gaining momentum, revolutionizing the design and optimization of RNA molecules while predicting intricate interactions, thereby expediting the complex drug discovery and development processes. Moreover, the advent of RNA editing and modulation techniques, including CRISPR-Cas and base editing, has kindled a new era by enabling direct modifications to RNA molecules. This pioneering avenue allows for correcting genetic mutations and regulating gene expression linked to diseases. Another compelling facet is the exploration of combination therapies, where researchers delve into the potential synergies between RNA-based treatments and other therapeutic avenues like immunotherapies and small molecule drugs, fostering heightened therapeutic outcomes. These collective trends exemplify the vibrant evolution of RNA-based approaches, underscoring their potential to revolutionize medical paradigms.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • FutureWise research report will help you understand the growth prospects, key trends, and data points affecting the market's growth.
  • A detailed review of strategies being opted by the players in this market, and a thorough market share registered by the key companies globally as well as on a regional basis.
  • To provide with an exhaustive analysis on the of RNA based Therapeutics and Vaccines Market By Product Type, By Indication Type and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   RNA based Therapeutics and Vaccines Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of RNA based Therapeutics and Vaccines Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   RNA based Therapeutics and Vaccines Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   RNA based Therapeutics and Vaccines Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. RNA-based Therapeutics
         1.1. siRNA
         1.2. miRNA
        2. RNA-based Vaccines
         2.1. mRNA

  • 8.   RNA based Therapeutics and Vaccines Market, By Indication Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oncology
        2. Immunology
        3. Ophthalmology
        4. Cardiovascular Diseases
        5. Infectious Diseases
        6. Genetic Diseases
        7. Others

  • 9.   North America RNA based Therapeutics and Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America RNA based Therapeutics and Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe RNA based Therapeutics and Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific RNA based Therapeutics and Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Alnylam Pharmaceuticals, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Arbutus Biopharma Corp.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Arrowhead Pharmaceuticals, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. BioNTech AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. CureVac AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Dicerna Pharmaceuticals, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Regulus Therapeutics, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Marina Biotech, Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. miRagen Therapeutics
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Moderna Therapeutics, Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Quark Pharmaceuticals, Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Santaris Pharma A/S (A Roche Company)
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Sylentis S.A.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients